Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity

What Was Tested

The trial (not phased) is built around NAD+.

It had three arms (groups): NMN 250 (experimental), NMN 500 (experimental) and Placebo (placebo comparator).

NMN-free placebo tablet.

The registry classes the interventions as dietary supplement and other.

Who Took Part

Enrollment: 131 actual participants took part.

It was open to men only aged from 20 years up to 49 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Body Mass Index ranging from 20 to 28 kg/m2(bounds included);. Body weight between of 70 kg to 100 kg (including limits);. Able to provide written informed consent to participate;. Having a moderate level of physical activity according to the Global Physical Activity Questionnaire (GPAQ);. Having a sport practice involving endurance or split races (including collective or individual sports) or cycling.

The full record lists 6 inclusion and 13 exclusion criteria; among the exclusions: having a mental state that does not allow them to give free and informed consent to participate in the study;; having history of a recent (less than 3 months) lower extremity muscle injury;; presenting a depressive syndrome;.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on NAD+, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2021-03-09 with completion listed for 2022-11-10.

It ran at 1 site in France.

Its stated primary purpose is supportive care.

What Was Measured

The main thing measured (primary outcome): Evolution of muscle recovery (time frame: before and after 21 and 38 days of treatment).

It also tracked 7 secondary outcomes, for example Changes in physical capacity, Changes in cardiorespiratory recovery, Changes in the perception of the arduousness of the effort, Changes in blood lactate levels before and after physical exercise, Changes in the perception of the intensity of post-exercise muscle pain (cramps) and Changes in the body composition.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 131 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.